This retrospective study aims to clarify the association between epidermal growth factor receptor (EGFR) mutation types and brain metastasis incidence in early-stage non-small-cell lung cancer after surgery.
Methods:
Patients pathologically diagnosed with stage I to III non-small-cell lung cancer were consecutively enrolled from January 2010 to January 2017 and reviewed. First-generation TKIs were selected as postoperative therapy for those with EGFR mutations, and platinum-based chemotherapy was used as postoperative therapy for patients with negative wild-type gene mutations. A Kaplan–Meier approach was used to calculate the cumulative incidence of brain metastasis and overall survival. Candidate prognostic factors were checked by log-rank test.
Results:
A total of 669 patients were eligible for the study, comprising 309 who were EGFR(+), and 360 who were EGFR(−). Patients with any type of EGFR mutation have a significantly higher risk of developing brain metastases compared to those with EGFR wild-type (hazard ratio=1.957, P=0.012). The incidence of brain metastasis was 17.1% higher in patients with the 19Del mutation than in those with the L858R mutation (13.6%), other mutations (13.3%), or wild-type EGFR (6.1%). Moreover, those with 19Del mutations showed the greatest increase in incidence of brain metastasis (hazard ratio=3.009, P=0.001); those with L858R mutations showed a smaller increase (hazard ratio=2.750, P=0.003).
Conclusions:
EGFR mutations are predictive factors for the cumulative incidence of brain metastasis. EGFR-mutant non-small-cell lung cancer patients may need more frequent brain magnetic resonance imaging to detect earlier occurrence of brain metastases, allowing for timely and effective treatment to improve patient prognosis.
LuoGZhangYRumgayH, et al. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Resp Med2025; 13(4):348-63.
2.
ZhangYLYuanJQWangKF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget2016; 7(48), 78985-78993.
3.
GeMZhuangYZhouX, et al. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases. J Neuro-Oncol2017; 135: 413-418.
4.
HanGBiJTanW, et al. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?Oncotarget2016; 7: 56998-57010.
5.
LinJJCardarellaSLydonCA, et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol, 2016; 11(4) 556-565.
6.
LeducCMerlioJPBesseB, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol2017; 28: 2715-2724.
7.
ZhouCWuYLChenG, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol2011; 12(8), 735-42.
8.
MitsudomiTMoritaSYatabeY, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol2010; 11(2), 121-128.
9.
ZhangJYuJSunX, et al. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer. Cancer Lett2014; 351(1), 6-12.
10.
LuoSChenLChenX, et al. Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases. Oncotarget2015; 6(18),16725-16734.
11.
HerbstRSWuYLJohnT, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: Updated results from the phase III randomized ADAURA trial. J Clin Oncol2023; 41(10), 1830-1840.
12.
YangZZhangYLiR, et al. Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial. Neuro-Oncology2021; 23(6), 967-978.
13.
RamalingamSSVansteenkisteJPlanchardD, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. New Engl J med2020; 41-50.
14.
NepoteAPolettoSBertagliaV, et al. Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review. Crit Rev Oncol Hemat2025; 205:104540.
15.
DetterbeckFCBoffaDJKimAW, et al. The eighth edition lung cancer stage classification. Chest2017; 151(1), 193-203.
16.
JinJZhouXLiangX, et al. Brain metastases as the first symptom of lung cancer: a clinical study from an Asian medical center. J Cancer Res Clin2013; 139: 403-408.
17.
JiangTSuCLiX, et al. EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases. J Thorac Oncol2016; 11: 1718-1728.
18.
ParkYWAnCLeeJ, et al. Diffusion tensor and postcontrast T1-weighted imaging radiomics to differentiate the epidermal growth factor receptor mutation status of brain metastases from non-small cell lung cancer. Neuroradiology2021; 63: 343-352.
19.
StanicKZwitterMHitijNT, et al. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol2014; 48: 173-183.
20.
ChangWYWuYLSuPLYangSCLinCCSuWC.The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. PLoS One2018; 13(2), e192161.
21.
LiHTongFMengR, et al. E2F1-mediated repression of WNT5A expression promotes brain metastasis dependent on the ERK1/2 pathway in EGFR-mutant non-small cell lung cancer. CMLS-Cell Mol Life S2021; 78: 2877-2891.
22.
BiswasAKHanSTaiY, et al. Targeting S100A9-ALDH1A1-retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer. Cancer Discov2022; 12(4), 1002-1021.
23.
HeonSYeapBYBrittGJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Re, 2010; 16(23), 5873-5882.
24.
BallardPYatesJWYangZ, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res2016; 22(20), 5130-5140.
25.
WuYLTsuboiMHeJ, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. Clin Cancer Res2020; 22(20), 1711-1723.
26.
SudaKMitsudomiTShintaniY, et al. Clinical impacts of EGFR mutation status: Analysis of 5780 surgically resected lung cancer cases. Ann Thorac Surg2021; 111: 269-276.
27.
KosakaTYatabeYOnozatoRKuwanoHMitsudomiT. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009, 4(1), 22-29.
28.
DengCZhangYMaZ, et al. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. J Thorac Cardiov Sur2021; 162(3), 664-674.
29.
StraussGMHerndonJEMaddausMA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol2008; 5043-5051.
30.
ArriagadaRBergmanBDunantA, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New Engl J Med2004; 350(4), 351-360.
31.
PignonJPTribodetHScagliottiGV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol2008; 26(21), 3552-3559.
32.
KellyKAltorkiNKEberhardtWE, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial. J Clin Oncol2015; 33(34), 4007-4014.
33.
ZhongWZWangQMaoWM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: Final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol2021; 39(7), 713-722.
34.
ChangWYWuYLSuPLYangSCLinCCSuWC. The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. PLoS One2018; 13(2), e192161.
35.
TanCSChoBCSooRA.Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?Lung Cancer2017; 108(null), 29-37.
36.
Godinho-PereiraJGarciaARFigueiraI, et al. Behind brain metastases formation: cellular and molecular alterations and blood-brain barrier disruption. Int J Mol Sci2021; 22(13), 22.
37.
KongLLWangLLXingLG, et al. Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases. Chronic Dis Transl Med2017; 3: 221-229.
38.
HsiaoSChouYLinS, et al. Brain metastases in patients with non-small cell lung cancer: the role of mutated-EGFRs with an exon 19 deletion or L858R point mutation in cancer cell dissemination. Oncotarget2017; 8: 53405-53418.
